APO RESEARCH · REPORT
Liraglutide
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
Product & engineering
Understand the product.
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
Selected research
Market Structure
Global Liraglutide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
The global Liraglutide market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Liraglutide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Europe market for Liraglutide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Asia Pacific market for Liraglutide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Liraglutide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Liraglutide include HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, Wuxi Asiapeptide and AmbioPharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Liraglutide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Liraglutide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Liraglutide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liraglutide market size, projected growth trends, production technologies, key applications, and end-use industries.
Liraglutide Segment by Company
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide
AmbioPharm
Liraglutide Segment by Type
Pills
Liquid
Liraglutide Segment by Application
Hospital
Drug Store
Liraglutide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liraglutide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liraglutide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liraglutide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Liraglutide market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liraglutide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liraglutide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Liraglutide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Pills
- Liquid
Applications
- Hospital
- Drug Store
Companies covered
- HEC Pharm
- Bachem
- Bharat Pharmaceuticals
- Kingpep Biotechnology
- Shenzhen JYMed Technology
- Wuxi Asiapeptide
- AmbioPharm
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Liraglutide Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Liraglutide Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Liraglutide Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Liraglutide Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Liraglutide Market Dynamics
- 2.1 Liraglutide Industry Trends
- 2.2 Liraglutide Industry Drivers
- 2.3 Liraglutide Industry Opportunities and Challenges
- 2.4 Liraglutide Industry Restraints
3 Liraglutide Market by Manufacturers
- 3.1 Global Liraglutide Revenue by Manufacturers (2021-2026)
- 3.2 Global Liraglutide Sales by Manufacturers (2021-2026)
- 3.3 Global Liraglutide Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Liraglutide Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Liraglutide Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Liraglutide Manufacturers, Product Type & Application
- 3.7 Global Liraglutide Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Liraglutide Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Liraglutide Players Market Share by Revenue in 2025
- 3.8.3 2025 Liraglutide Tier 1, Tier 2, and Tier 3
4 Liraglutide Market by Type
- 4.1 Liraglutide Type Introduction
- 4.1.1 Pills
- 4.1.2 Liquid
- 4.2 Global Liraglutide Sales by Type
- 4.2.1 Global Liraglutide Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Liraglutide Sales by Type (2021-2032)
- 4.2.3 Global Liraglutide Sales Market Share by Type (2021-2032)
- 4.3 Global Liraglutide Revenue by Type
- 4.3.1 Global Liraglutide Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Liraglutide Revenue by Type (2021-2032)
- 4.3.3 Global Liraglutide Revenue Market Share by Type (2021-2032)
5 Liraglutide Market by Application
- 5.1 Liraglutide Application Introduction
- 5.1.1 Hospital
- 5.1.2 Drug Store
- 5.2 Global Liraglutide Sales by Application
- 5.2.1 Global Liraglutide Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Liraglutide Sales by Application (2021-2032)
- 5.2.3 Global Liraglutide Sales Market Share by Application (2021-2032)
- 5.3 Global Liraglutide Revenue by Application
- 5.3.1 Global Liraglutide Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Liraglutide Revenue by Application (2021-2032)
- 5.3.3 Global Liraglutide Revenue Market Share by Application (2021-2032)
6 Global Liraglutide Sales by Region
- 6.1 Global Liraglutide Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Liraglutide Sales by Region (2021-2032)
- 6.2.1 Global Liraglutide Sales by Region (2021-2026)
- 6.2.2 Global Liraglutide Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Liraglutide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Liraglutide Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Liraglutide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Liraglutide Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Liraglutide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Liraglutide Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Liraglutide Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Liraglutide Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Liraglutide Revenue by Region
- 7.1 Global Liraglutide Revenue by Region
- 7.1.1 Global Liraglutide Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Liraglutide Revenue by Region (2021-2026)
- 7.1.3 Global Liraglutide Revenue by Region (2027-2032)
- 7.1.4 Global Liraglutide Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Liraglutide Revenue (2021-2032)
- 7.2.2 North America Liraglutide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Liraglutide Revenue (2021-2032)
- 7.3.2 Europe Liraglutide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Liraglutide Revenue (2021-2032)
- 7.4.2 Asia-Pacific Liraglutide Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Liraglutide Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Liraglutide Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 HEC Pharm
- 8.1.1 HEC Pharm Company Information
- 8.1.2 HEC Pharm Business Overview
- 8.1.3 HEC Pharm Liraglutide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 HEC Pharm Liraglutide Product Portfolio
- 8.1.5 HEC Pharm Recent Developments
- 8.2 Bachem
- 8.2.1 Bachem Company Information
- 8.2.2 Bachem Business Overview
- 8.2.3 Bachem Liraglutide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Bachem Liraglutide Product Portfolio
- 8.2.5 Bachem Recent Developments
- 8.3 Bharat Pharmaceuticals
- 8.3.1 Bharat Pharmaceuticals Company Information
- 8.3.2 Bharat Pharmaceuticals Business Overview
- 8.3.3 Bharat Pharmaceuticals Liraglutide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Bharat Pharmaceuticals Liraglutide Product Portfolio
- 8.3.5 Bharat Pharmaceuticals Recent Developments
- 8.4 Kingpep Biotechnology
- 8.4.1 Kingpep Biotechnology Company Information
- 8.4.2 Kingpep Biotechnology Business Overview
- 8.4.3 Kingpep Biotechnology Liraglutide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Kingpep Biotechnology Liraglutide Product Portfolio
- 8.4.5 Kingpep Biotechnology Recent Developments
- 8.5 Shenzhen JYMed Technology
- 8.5.1 Shenzhen JYMed Technology Company Information
- 8.5.2 Shenzhen JYMed Technology Business Overview
- 8.5.3 Shenzhen JYMed Technology Liraglutide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Shenzhen JYMed Technology Liraglutide Product Portfolio
- 8.5.5 Shenzhen JYMed Technology Recent Developments
- 8.6 Wuxi Asiapeptide
- 8.6.1 Wuxi Asiapeptide Company Information
- 8.6.2 Wuxi Asiapeptide Business Overview
- 8.6.3 Wuxi Asiapeptide Liraglutide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Wuxi Asiapeptide Liraglutide Product Portfolio
- 8.6.5 Wuxi Asiapeptide Recent Developments
- 8.7 AmbioPharm
- 8.7.1 AmbioPharm Company Information
- 8.7.2 AmbioPharm Business Overview
- 8.7.3 AmbioPharm Liraglutide Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 AmbioPharm Liraglutide Product Portfolio
- 8.7.5 AmbioPharm Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Liraglutide Value Chain Analysis
- 9.1.1 Liraglutide Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Liraglutide Production Mode & Process
- 9.2 Liraglutide Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Liraglutide Distributors
- 9.2.3 Liraglutide Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst